Renin-angiotensin gene polymorphisms and neurohormonal inhibition.
Analyses of polymorphisms in the renin-angiotensin system may never completely predict responsiveness to pharmacotherapy that blocks angiotensin-converting enzyme or the angiotensin receptor type 1. However, the pharmacogenetic studies that have been conducted to date are intriguing, and they illustrate the potential benefit of designing larger genome-wide clinical studies. Such studies will continue to define the role of renin-angiotensin pharmacogenetics in patients with heart failure due to underlying cardiac dysfunction.
Pauly
Daniel F
DF
Division of Cardiovascular Medicine, Section of Heart Failure and Transplantation, University of Florida College of Medicine, Box 100277, Gainesville, FL 32610, USA. paulydf@medicine.ufl.edu
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008403:Mass Screening; D011110:Polymorphism, Genetic; D011945:Receptors, Angiotensin / Q000235:genetics; D011955:Receptors, Drug / Q000187:drug effects / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000235:genetics*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011945:Receptors, Angiotensin; D011955:Receptors, Drug